Biofrontera Group
Pharmaceuticals, 120 Presidential Way Ste 330, Leverkusen, Massachusetts, 01801, United States, 51-200 Employees
Phone Number: +16*********
Who is BIOFRONTERA GROUP
Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics. The Germany-based company develops and markets innova...
Read More
-
Headquarters: 120 Presidential Way Ste 330, Leverkusen, Massachusetts, 01801, United States
-
Date Founded: 1997
-
Employees: 51-200
-
Revenue: $10 Million to $25 Million
-
Active Tech Stack: See technologies
Industry: Pharmaceuticals
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from BIOFRONTERA GROUP
Biofrontera Group Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding Biofrontera Group
Answer: Biofrontera Group's headquarters are located at 120 Presidential Way Ste 330, Leverkusen, Massachusetts, 01801, United States
Answer: Biofrontera Group's phone number is +16*********
Answer: Biofrontera Group's official website is https://biofrontera.com
Answer: Biofrontera Group's revenue is $10 Million to $25 Million
Answer: Biofrontera Group's SIC: 2834
Answer: Biofrontera Group's NAICS: 325412
Answer: Biofrontera Group has 51-200 employees
Answer: Biofrontera Group is in Pharmaceuticals
Answer: Biofrontera Group contact info: Phone number: +16********* Website: https://biofrontera.com
Answer: Biofrontera AG is a biopharmaceutical company specializing in the development and sale of dermatological drugs and medical cosmetics. The Germany-based company develops and markets innovative products for the care, protection and treatment of the skin. The companys lead product is the combination of Ameluz, a topical prescription drug, and medical device BF-RhodoLED for the photodynamic therapy of certain superficial skin cancers and their precursors. Ameluz has been marketed in the EU since 2012 and in the United States since May 2016. In the EU, the company also sells the dermocosmetics series Belixos, which offers specialized care for damaged or diseased skin. Biofrontera is the first German pharmaceutical company to receive a centralized European and a US approval for a drug developed in-house. The Biofrontera Group was founded in 1997 and is listed on the Frankfurt Stock Exchange (ticker symbol: B8F) and on the US NASDAQ (ticker symbol: BFRA).
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month